NEW YORK, Oct. 19 /PRNewswire/ — Reportlinker.com announces
that a new market research report is available in its
catalogue:
http://www.reportlinker.com/p0315764/Prostate-Cancer-Drug-Futures.html
AN EXCEPTIONALLY COST EFFECTIVE SERVICE INCLUDING FORMATS TO
MEET EVERY INFORMATION NEED
Espicom’s Prostate Cancer Drug Futures includes formats to meet
differing information requirement of customers. For constant
vigilance and up-to-date coverage of lung cancer drug development
users can access the 24/7 daily updated web service. For strategic
periodic reviews we also provide quarterly-updated reports of all
drugs in a convenient pdf document.
24/7 web access
Quarterly updated pdf reports
Single cost-effective price
All updates including any new drugs added during your license
period
Related news
Espicom’s research methodology for forecasting and including an
explanation of the competitor ratio analysis scoring system.
The prostate cancer (PC) market is on the verge of considerable
change….
….with the imminent arrival of new targeted therapies that
will prolong patient survival. PC is the second leading cause of
new cancer cases in men worldwide and the sixth leading cause of
cancer death in men. In the US, over two million men currently
suffer with PC and it is estimated that there were 192,311 new
cases and 29,698 deaths due to the disease in 2008. There have been
dramatic improvements in PC survival over the last 25 years, mainly
due to a combination of earlier diagnosis and improvements in
treatments, although rates vary between countries
The PC market was estimated to be worth US$5.2 billion in
2008;
‘/>”/>
